Esophageal Squamous Cell Carcinoma
Conditions
Interventions
Endoscopic biopsy group:None
Sponsors
The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: Surgical resection group: 1) Aged 40–75 years; 2) Patients with histopathologically confirmed esophageal carcinoma undergoing surgical resection. Endoscopic biopsy group: 1) Aged 40–75 years; 2) Patients with histopathologically confirmed esophageal carcinoma requiring pretreatment endoscopic biopsy for immunotherapy.
Exclusion criteria
Exclusion criteria: 1) Patients with prior radiotherapy; 2) Patients with prior chemotherapy; 3) Patients with prior immunotherapy; 4) Patients receiving any other anticancer therapy or having concomitant conditions that may compromise tumor cell viability or organoid establishment; 5) Patients with hematologic malignancies (e.g., leukemia) or active severe infections that may alter peripheral blood immune cell profiles; 6) Patients under medication or with conditions potentially affecting peripheral blood immunophenotyping; 7) Patients declining biospecimen donation or unwilling to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality and Success Rate of Esophageal Cancer Organoid Immune Co-Culture Model;Organoid-Based Predictive Model Performance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive Detection Rate of Predictive Biomarkers;Key Mechanisms Influencing Therapeutic Response;Clinical Consistency of Organoid Drug Sensitivity-Guided Therapy;In Vitro Response Rate of Immunotherapy-Related Novel Drugs;In Vitro Response Rate of New Drugs Related to Radiotherapy and Chemotherapy;Tumor-Specific Killing Efficiency of TCR-T Therapy; | — |
Countries
China
Contacts
Public ContactLuowei Wang
The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)
Outcome results
None listed